(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(0.12%) $82.73
(0.94%) $2.05
(-0.43%) $2 347.50
(-0.80%) $27.44
(-0.16%) $960.00
(-0.22%) $0.933
(-0.34%) $10.99
(-0.54%) $0.796
(1.55%) $93.30
@ NOK33.60
发出时间: 29 Apr 2024 @ 19:26
回报率: 0.00%
上一信号: Apr 29 - 17:04
上一信号:
回报率: 0.00 %
Live Chart Being Loaded With Signals
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics...
Stats | |
---|---|
今日成交量 | 15 687.00 |
平均成交量 | 82 252.00 |
市值 | 585.74M |
EPS | NOK0.390 ( 2023-11-01 ) |
下一个收益日期 | ( NOK0 ) 2024-05-31 |
Last Dividend | NOK0.998 ( 2010-04-13 ) |
Next Dividend | NOK0 ( N/A ) |
P/E | 28.47 |
ATR14 | NOK0.900 (2.68%) |
音量 相关性
Navamedic ASA 相关性
10 最正相关 | |
---|---|
NORSE.OL | 0.895 |
SMOP.OL | 0.871 |
NTEL.OL | 0.871 |
TOM.OL | 0.868 |
ENDUR.OL | 0.839 |
XXL.OL | 0.838 |
KIT.OL | 0.832 |
SNI.OL | 0.826 |
BORR.OL | 0.815 |
AYFIE.OL | 0.813 |
10 最负相关 | |
---|---|
AKBM.OL | -0.895 |
ODL.OL | -0.895 |
SCATC.OL | -0.893 |
SBX.OL | -0.87 |
OKEA.OL | -0.858 |
VOLUE.OL | -0.857 |
PHO.OL | -0.854 |
FRO.OL | -0.852 |
TRVX.OL | -0.846 |
XPLRA.OL | -0.842 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Navamedic ASA 相关性 - 货币/商品
Navamedic ASA 财务报表
Annual | 2023 |
营收: | NOK512.00M |
毛利润: | NOK199.05M (38.88 %) |
EPS: | NOK0 |
FY | 2023 |
营收: | NOK512.00M |
毛利润: | NOK199.05M (38.88 %) |
EPS: | NOK0 |
FY | 2022 |
营收: | NOK382.14M |
毛利润: | NOK163.52M (42.79 %) |
EPS: | NOK1.750 |
FY | 2021 |
营收: | NOK278.44M |
毛利润: | NOK111.74M (40.13 %) |
EPS: | NOK0.00774 |
Financial Reports:
No articles found.
Navamedic ASA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
NOK0 (N/A) |
NOK0 (N/A) |
NOK0 (N/A) |
NOK0 (N/A) |
NOK0 (N/A) |
NOK0 (N/A) |
NOK0 (N/A) |
NOK0 (N/A) |
NOK0 (N/A) |
NOK0 (N/A) |
First Dividend | NOK0.998 | 2010-04-13 |
Last Dividend | NOK0.998 | 2010-04-13 |
Next Dividend | NOK0 | N/A |
Payout Date | 2010-04-27 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | NOK0.998 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.02 | -- |
Div. Sustainability Score | 5.91 | |
Div.Growth Potential Score | 0.831 | |
Div. Directional Score | 3.37 | -- |
Year | Amount | Yield |
---|---|---|
2010 | NOK0.998 | 17.80% |
2011 | NOK0 | 0.00% |
2012 | NOK0 | 0.00% |
2013 | NOK0 | 0.00% |
2014 | NOK0 | 0.00% |
2015 | NOK0 | 0.00% |
2016 | NOK0 | 0.00% |
2017 | NOK0 | 0.00% |
2018 | NOK0 | 0.00% |
2019 | NOK0 | 0.00% |
2020 | NOK0 | 0.00% |
2021 | NOK0 | 0.00% |
2022 | NOK0 | 0.00% |
2023 | NOK0 | 0.00% |
2024 | NOK0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
ALNG.OL | Dividend King | 2023-11-27 | Quarterly | 2 | 6.60% | 7.04 |
OKEA.OL | Dividend Knight | 2023-12-01 | Quarterly | 3 | 5.65% | 6.86 |
SALM.OL | Dividend Knight | 2023-06-09 | Annually | 17 | 2.80% | 4.97 |
BWLPG.OL | Dividend Knight | 2023-11-17 | Quarterly | 11 | 1.68% | 4.46 |
ELK.OL | Dividend Knight | 2023-05-02 | Annually | 6 | 6.64% | 4.31 |
BWO.OL | Dividend Knight | 2023-11-20 | Quarterly | 14 | 0.87% | 3.96 |
ATEA.OL | Dividend Knight | 2023-11-20 | Annually | 16 | 2.97% | 3.45 |
HAFNI.OL | Dividend Knight | 2023-11-23 | Semi-Annually | 5 | 1.18% | 3.31 |
AKER.OL | Dividend Knight | 2023-11-07 | Semi-Annually | 20 | 2.99% | 3.13 |
AUSS.OL | Dividend Knight | 2023-05-26 | Annually | 17 | 3.23% | 2.93 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00752 | 1.500 | 9.85 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00735 | 1.200 | 9.76 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0175 | 1.500 | -0.916 | -1.374 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.111 | 0.800 | 9.44 | 7.56 | [1 - 3] |
quickRatioTTM | 0.469 | 0.800 | -1.948 | -1.558 | [0.8 - 2.5] |
cashRatioTTM | 0.201 | 1.500 | 9.99 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.287 | -1.500 | 5.22 | -7.83 | [0 - 0.6] |
interestCoverageTTM | 2.30 | 1.000 | -0.260 | -0.260 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0520 | 2.00 | -0.0173 | -0.0346 | [0 - 30] |
freeCashFlowPerShareTTM | -0.180 | 2.00 | -0.0898 | -0.180 | [0 - 20] |
debtEquityRatioTTM | 0.675 | -1.500 | 7.30 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.378 | 1.000 | 7.03 | 7.03 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0404 | 1.000 | -1.192 | -1.192 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.00595 | 1.000 | -1.144 | -1.144 | [0.2 - 2] |
assetTurnoverTTM | 0.977 | 0.800 | 6.82 | 5.46 | [0.5 - 2] |
Total Score | 5.91 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 152.06 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0175 | 2.50 | -0.589 | -1.374 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.180 | 2.00 | -0.0598 | -0.180 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0520 | 2.00 | -0.0173 | -0.0346 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.751 | 1.500 | 1.657 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.00175 | 1.000 | -2.54 | 0 | [0.1 - 0.5] |
Total Score | 0.831 |
Navamedic ASA
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。